FDA Accepts Dapagliflozin Application from Centaur Pharmaceuticals
The FDA has accepted the application ANDA220679 for dapagliflozin from Centaur Pharmaceuticals.
Company
Pharmaceutical intelligence for Centaur Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
The FDA has accepted the application ANDA220679 for dapagliflozin from Centaur Pharmaceuticals.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.